Synapse

← Hagop M. Kantarjian

Papers by Hagop M. Kantarjian

Page 13 · newest first

  1. Significance of recurrence of minimal residual disease detected by multi‐parameter flow cytometry in patients with acute lymphoblastic leukemia in morphological remissionAmerican Journal of Hematology · 2017
  2. Phase II Study of Prophylactic Non-Irradiated Granulocyte Transfusions in AML Patients Receiving Induction ChemotherapyJournal of Blood Disorders & Transfusion · 2017
  3. Poor outcomes associated with +der(22)t(9;22) and −9/9p in patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitorAmerican Journal of Hematology · 2016
  4. Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumabBlood · 2016
  5. Hemophagocytic lymphohistiocytosis in adults: An under recognized entityBBA Clinical · 2016
  6. US intergroup study of chemotherapy plus dasatinib and allogeneic stem cell transplant in Philadelphia chromosome positive ALLBlood Advances · 2016
  7. Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemiaHaematologica · 2016
  8. Ph-like acute lymphoblastic leukemia: a high-risk subtype in adultsBlood · 2016
  9. Enasidenib (AG-221), a Potent Oral Inhibitor of Mutant Isocitrate Dehydrogenase 2 (IDH2) Enzyme, Induces Hematologic Responses in Patients with Myelodysplastic Syndromes (MDS)Blood · 2016
  10. Cladribine Combined with Idarubicin and Ara-C (CLIA) As a Frontline and Salvage Treatment for Young Patients (≤65 yrs) with Acute Myeloid LeukemiaBlood · 2016
  11. Cryptic Philadelphia Chromosome in Newly Diagnosed Chronic Phase CML (CML-CP): Clinical Characteristics and Treatment Outcome after Treatment with 5 TKI ModalitiesBlood · 2016
  12. Chronic myeloid leukemia: sequencing of TKI therapiesHematology · 2016
  13. Determination of IDH1 Mutational Burden and Clearance Via Next-Generation Sequencing in Patients with IDH1 Mutation-Positive Hematologic Malignancies Receiving AG-120, a First-in-Class Inhibitor of Mutant IDH1Blood · 2016
  14. Nivolumab Combined with Ibrutinib for CLL and Richter Transformation: A Phase II TrialBlood · 2016
  15. BRD4 Proteolysis Targeting Chimera (PROTAC) ARV-825, Causes Sustained Degradation of BRD4 and Modulation of Chemokine Receptors, Cell Adhesion and Metabolic Targets in Leukemia Resulting in Profound Anti-Leukemic EffectsBlood · 2016
  16. Mutational Landscape of Pediatric Acute Lymphoblastic LeukemiaBlood · 2016
  17. Results from Ongoing Phase 2 Trial of SL-401 As Consolidation Therapy in Patients with Acute Myeloid Leukemia (AML) in Remission with High Relapse Risk Including Minimal Residual Disease (MRD)Blood · 2016
  18. Phase IB/II Study of Nivolumab in Combination with Azacytidine (AZA) in Patients (pts) with Relapsed Acute Myeloid Leukemia (AML)Blood · 2016
  19. NCCN Guidelines Insights: Chronic Myeloid Leukemia, Version 1.2017Journal of the National Comprehensive Cancer Network · 2016
  20. Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung CancersClinical Cancer Research · 2016
  21. Dorsal column myelopathy after intrathecal chemotherapy for leukemiaAmerican Journal of Hematology · 2016
  22. Mutational Landscape of Pediatric Acute Lymphoblastic LeukemiaCancer Research · 2016
  23. Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemiaNature Communications · 2016
  24. Long-term Follow-up of Treatment with Ibrutinib and Rituximab in Patients with High-Risk Chronic Lymphocytic LeukemiaClinical Cancer Research · 2016
  25. Phase 2 study of low‐dose clofarabine plus cytarabine for patients with higher‐risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agentsCancer · 2016
  26. Concomitant use of direct-acting antivirals and chemotherapy in hepatitis C virus-infected patients with cancerAlimentary Pharmacology & Therapeutics · 2016
  27. Prognostic impact of pretreatment cytogenetics in adult P hiladelphia chromosome–negative acute lymphoblastic leukemia in the era of minimal residual diseaseCancer · 2016
  28. An accurate, simple prognostic model consisting of age, JAK2 , CALR , and MPL mutation status for patients with primary myelofibrosisHaematologica · 2016
  29. Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemiasAmerican Journal of Hematology · 2016
  30. Phase I/II study of low-dose azacytidine in patients with chronic myeloid leukemia who have minimal residual disease while receiving therapy with tyrosine kinase inhibitorsLeukemia & lymphoma/Leukemia and lymphoma · 2016
  31. Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemiaCancer · 2016
  32. Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cellsScience Translational Medicine · 2016
  33. Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B‐cell acute lymphoblastic leukemiaCancer · 2016
  34. International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemiaHaematologica · 2016
  35. Peripheral blood blast clearance is an independent prognostic factor for survival and response to acute myeloid leukemia induction chemotherapyAmerican Journal of Hematology · 2016
  36. Cytopenia levels for aiding establishment of the diagnosis of myelodysplastic syndromesBlood · 2016
  37. Long‐term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinibAmerican Journal of Hematology · 2016
  38. Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous LeukemiaCancer Discovery · 2016
  39. Outcome of Patients With Therapy-Related Acute Myeloid Leukemia With or Without a History of MyelodysplasiaClinical Lymphoma Myeloma & Leukemia · 2016
  40. A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phaseCancer · 2016
  41. Clinical use of ruxolitinib in an academic medical center in unselected patients with myeloproliferative neoplasms not on clinical studyLeukemia & lymphoma/Leukemia and lymphoma · 2016
  42. Role of neoplastic monocyte-derived fibrocytes in primary myelofibrosisThe Journal of Experimental Medicine · 2016
  43. Hyper‐CVAD plus ponatinib versus hyper‐CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia: A propensity score analysisCancer · 2016
  44. Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cellsJournal of Clinical Investigation · 2016
  45. Clinical and molecular characteristics of XPO1 mutations in patients with chronic lymphocytic leukemiaAmerican Journal of Hematology · 2016
  46. TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomesCancer · 2016
  47. MLN0128, a novel mTOR kinase inhibitor, disrupts survival signaling and triggers apoptosis in AML and AML stem/ progenitor cellsOncotarget · 2016
  48. Time-dependent changes in mortality and transformation risk in MDSBlood · 2016
  49. Complete remission in a patient with JAK2- and IDH2-positive myelofibrosisBlood · 2016
  50. Long‐term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trialBritish Journal of Haematology · 2016